Pratel

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pratel

Property	Description
Active Ingredients	Praziquantel, Pyrantel Pamoate
Form	Tablet (Chewable/Standard)
Pharmacological Class	Anthelmintic (Broad-Spectrum Antiparasitic)
Common Use (General)	Comprehensive parasitic worm clearance
Origin	Synthetic

Defining Pratel: Fixed Combination and Pharmacological Class

Pratel is defined as a synthetic veterinary medicinal product belonging to the anthelmintic pharmacological class, which is specifically used to manage and expel parasitic worms, or helminths, from the host organism. It is formulated as a fixed combination product, strategically integrating two distinct active chemical entities to achieve a wider therapeutic spectrum. Pratel is typically presented as a tablet or chewable tablet designed for oral administration in dogs and cats. Pharmacological studies have clinically recognized that combining agents in this manner enhances the drug's utility by simplifying the complex process of treating multiple concurrent parasite types.

Pratel’s Dual Composition: Praziquantel and Pyrantel Pamoate

The core identity of Pratel lies in its dual active ingredient composition: Praziquantel and Pyrantel Pamoate. Both components are synthetic in origin and are designed to act on different parasitic structures. Praziquantel provides coverage against flatworms, specifically cestodes (tapeworms), while Pyrantel Pamoate targets certain nematodes (roundworms and hookworms). The integration of both compounds into the tablet matrix, alongside necessary pharmaceutical excipients, is a distinguishing feature of the formulation. This fixed structure, frequently used in veterinary practice, provides a distinct advantage over single-ingredient dewormers that might necessitate separate treatments for different types of worms.

General Purpose: A Strategy for Comprehensive Parasite Clearance

The general therapeutic purpose of Pratel is to provide a reliable, broad-spectrum strategy for effective and comprehensive parasite clearance. By combining agents whose efficacy targets both major parasitic families—tapeworms and roundworms—the product is equipped to manage the most common types of mixed gastrointestinal parasitic infections simultaneously. This combined capability delivers the essential benefit of achieving robust clearance of parasitic burdens, supporting the overall physiological health and routine maintenance of the target animal.

Regulatory References

Praziquantel Drug Information

What side effects are possible with Pratel?

Possible Side Effects and Safety Information

The safety profile for any medication, including Pratel, is defined by clinical studies and post-marketing surveillance data, which are typically summarized in labeling approved by regulatory bodies like the U.S. FDA or the European Medicines Agency (EMA).

As with all medicinal products, exposure to Pratel may be associated with side effects, also known as adverse reactions. These effects are formally categorized based on how often they occur in the treated population, such as very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), or uncommon (may affect up to 1 in 100 people), according to standard international frequency classifications (e.g., ICH guidelines).

Serious adverse reactions, which include outcomes such as death, hospitalization, or life-threatening events, are rigorously tracked and must be promptly reported to regulatory agencies. The full safety information, including contraindications and warnings, is essential for defining the appropriate use of the medicine.

Specific safety considerations, such as use during pregnancy, lactation, or in pediatric populations, are detailed in official regulatory documents only if data from clinical trials or post-marketing experience are available to inform these decisions. Furthermore, any dose- or exposure-related safety patterns are explicitly stated within the official drug label to guide prescription practices and monitoring.

All patients are encouraged to refer to the comprehensive prescribing information provided by the manufacturer or their respective national regulatory authority for the complete, officially documented safety data.

Overdose and Emergency Response

Overdosage with the fixed combination of Praziquantel and Pyrantel Pamoate may result in an exaggeration of documented clinical effects, requiring immediate professional attention. The official regulatory profile identifies specific manifestations primarily affecting the gastrointestinal system and the central nervous system. These documented presentations include a cluster of symptoms such as Vomiting, Nausea, Diarrhea, and Abdominal cramps. Further reported systemic effects include Headache, Dizziness, and Drowsiness or decreased activity.

Overdose Manifestations	Management and Caution
Gastrointestinal distress, CNS symptoms	Treatment is symptomatic and supportive.
Potential for Severe Allergic Reactions	Caution is noted for individuals with Liver disease.

Official Regulatory Mandates

The immediate action mandated by regulatory guidance is to Contact a poison control center immediately upon suspected over-ingestion, or to contact a doctor or emergency medical services at once. Urgent medical assistance is required if the affected individual is symptomatic. The development of severe reactions, such as irregular breathing or swelling, also requires urgent professional assessment. Official documents classify management as symptomatic and supportive, as no specific antidote is known. Procedural constraints include the explicit instruction to not induce vomiting unless specifically directed by a medical professional.

Therapeutic Uses of Pratel

What Pratel Treats: Main Uses and Benefits

Comprehensive Clearance of Mixed Parasitic Infections

Pratel is commonly used across conditions presenting with systemic or localized discomfort caused by Gastrointestinal Helminthiasis, a condition involving simultaneous infestation by major types of parasitic worms (Tapeworms and Roundworms/Hookworms). The medication is commonly used to help with the combined therapeutic management of these infections. This application is relevant in contexts involving heightened systemic burden and is commonly used across domains where additional symptomatic support is needed.

Alleviation of Parasite-Driven Digestive Symptoms

The therapeutic benefit is generally applied in addressing symptom clusters that may become intense or disruptive, such as persistent diarrhea, vomiting, and weight loss that interfere with daily functioning. Clearing the parasite load generally contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Role in Routine Maintenance and Proactive Health

This combination is commonly used across conditions characterized by periods of heightened symptoms, and is relevant for managing symptoms in high-risk patient groups like Puppies, Kittens, and Adult Animals. This application is considered relevant for easing symptoms that become more disruptive during flare-ups and supports general well-being during symptomatic phases.

Common Symptom Focus: Digestive Discomfort

This medication is considered relevant for easing symptoms that interfere with daily functioning, such as symptoms related to physical discomfort and chronic or recurrent diarrhea.

Regulatory References

U.S. Food and Drug Administration's (FDA) regulations on the combined use of Praziquantel and Pyrantel Pamoate

Eligibility and Restrictions for Use

The eligibility for Pratel, a veterinary product containing Praziquantel and Pyrantel Pamoate, is defined by regulatory agencies based on the animal’s age, weight, reproductive status, and health status.

Eligibility Status	Applicable Populations (Official Labeling)
Contraindicated	Animals with a known hypersensitivity or allergy to Praziquantel, Pyrantel Pamoate, or any component.
Prohibited Age/Weight	Kittens less than 2 months of age or weighing less than 2.0 pounds; Puppies less than 3 weeks of age or weighing less than 2.0 pounds.
Restricted/Conditional	Pregnant animals, nursing animals, or those used for breeding (requires veterinary consultation/risk assessment). Sick or frail animals (requires veterinary consultation).

Use is generally established for adult dogs and cats and for those puppies and kittens that meet the minimum age and weight requirements defined in the regulatory documentation.

Official labeling classifies sick, weak, pregnant, or nursing animals as restricted-use populations. The law requires the product be administered by or on the order of a licensed veterinarian, especially when treating animals within these conditional categories.

What should I know about interactions with other medicines?

Based on the official regulatory documentation available for Pratel, which contains the active ingredients pyrantel embonate and praziquantel, the established interaction profile is specific and documented.

Documented Interaction Profile

Pratel is not intended for use in humans; therefore, its official interaction profile primarily focuses on veterinary use and the interaction of its active components with other animal-specific medicines. However, general principles regarding the human components are often noted in a product's full documentation, if applicable.

Interacting Product Category	Official Regulatory Statement
Piperazine Compounds	Concurrent use of Pratel is to be avoided. The anthelmintic effects of the active components (pyrantel) may be mutually antagonized by piperazine compounds.
Other Anthelmintics	Caution is advised regarding co-administration with other organophosphate or diethylcarbamazine-containing products.
Food or Supplements	No specific, clinically significant interactions with food or common supplements are consistently documented across regulatory guidance.

Summary of Interaction Constraints

The primary documented restriction is the avoidance of co-administration with other antiparasitic agents, specifically those containing piperazine, to prevent a reduction in the drug's effectiveness. This is a pharmacokinetic/pharmacodynamic interaction that results in a loss of the intended therapeutic action. For the other active component, praziquantel, its interaction profile is generally considered mild and non-clinically significant across most widely used co-administered products. Any potential drug-drug interactions, particularly those affecting metabolism or excretion, should be reviewed by a veterinarian before use.

Mechanism of Action

Dual Mechanisms for Parasite Neuromuscular Failure

This combination product employs two chemically distinct mechanisms to target major parasitic classes. The Pyrantel component targets nematodes (roundworms) by acting as an agonist at their nicotinic acetylcholine receptors, forcing a sustained overstimulation that results in spastic paralysis. Simultaneously, the Praziquantel component targets cestodes (tapeworms) by inducing a rapid, uncontrolled calcium ion influx through specific channels, which disrupts the parasite's Ca^2+ homeostasis.

Molecular Action Leading to Physical Clearance

The Ca^2+ surge caused by Praziquantel induces a tetanic contraction and rapid disintegration of the tapeworm's outer protective layer (tegument). The resulting physiological effect of both ingredients is the loss of muscle control and intestinal attachment capacity across both major parasitic groups. This functional incapacitation renders the parasites immobile, facilitating their physical expulsion from the digestive tract via the host's normal intestinal peristalsis.

Dosage and Administration Information

Pratel (praziquantel/pyrantel embonate) is an approved veterinary product administered via the oral route for use in dogs and cats. Proper use follows the instructions provided to ensure accurate dosing and administration.

Official Administration Guidelines

Scope Element	Official Instruction (Strictly Label-Based)
Route of Administration	Oral use (ingestion) only.
Dosing Schedule	The dose is weight-based, calculated to provide a minimum therapeutic amount of active substance per kilogram of body weight. The final dose is given according to a specific weight-based chart in whole or fractional tablets.
Timing and Food	Fasting is not required nor recommended before or after treatment. The tablet may be administered with or without food.
Preparation	The scored tablet is permitted to be divided into fractions (halves or quarters) for precise dosing or may be crumbled and mixed into a small amount of food to ensure full ingestion.
Age Restriction	The product is officially indicated for use only in puppies and kittens from 30 days of age onward.
Treatment Frequency	The standard use is a single oral dose for treatment; however, periodic treatment (e.g., three to four times a year) may be recommended for routine control.

Procedural Structure

Official use begins with accurately determining the animal's weight to calculate the number of tablets or tablet portions required. The dose must then be fully ingested by the animal in one administration. This defined, non-fasting, weight-dependent protocol is the mechanism described for the correct use of Pratel.

Recent Clinical Evidence

Research Evidence Overview of Studies for Pratel

Evidence for the Treatment of Mixed Intestinal Parasitic Infections

The research supporting the evaluation of the praziquantel and pyrantel pamoate combination is largely based on controlled laboratory efficacy studies and clinical field trials submitted to regulatory authorities. These studies were evaluated in conditions associated with parasitic worms, or helminths, including both tapeworms (cestodes) and roundworms/hookworms (nematodes). This research contributes to the required regulatory evidence for the fixed combination's evaluation in the presence of these common intestinal parasitic worms.

Research examined the simultaneous activity of both compounds in these research scenarios, and described a pattern where the two did not hinder each other's expected behavior. Reported observations included measured changes in parasite levels following the administration of the combination. Evidence contributes to the broader evidence landscape regarding the concurrent presence of multiple parasite types.

How Studies Measure the Effect (Primary Outcomes)

Research has explored the outcomes related to parasite levels. Research examined outcomes related to measured parasite change, which was often quantified using the Faecal Egg Count (FEC) reduction metric. This outcome describes the change in the number of parasite eggs found in stool samples during the study period.

In controlled settings, studies also monitored the physical recovery of adult parasites and segments to describe patterns of their measured change from the gastrointestinal tract. The findings help contextualize the measured outcomes related to systemic or functional imbalance.

Research in Target Animal Populations

The clinical evaluation for this combination was studied for dogs and cats. Studies included both adult animals and young animals (puppies and kittens), evaluating animals with naturally acquired infections or those that were experimentally infected for the purposes of the study. Findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Pratel (FAQ)

Q: What is Pratel used for?

A: Pratel is a combination drug used in dogs and cats to treat parasitic infections. It contains two active ingredients:

Pyrantel embonate (also called pyrantel pamoate): An anthelmintic (dewormer) used to treat infections caused by roundworms and hookworms.
Praziquantel: An anthelmintic primarily effective against tapeworms.

Pratel is used to treat infections with the following parasites:

Tapeworms: Dipylidium caninum, Taenia spp., Echinococcus granulosus, and Echinococcus multilocularis.
Roundworms (Ascarids): Toxocara canis, Toxocara cati, and Toxascaris leonina.
Hookworms: Ancylostoma caninum and Uncinaria stenocephala.

Q: How is Pratel typically given to a pet?

A: Pratel is an oral tablet that is usually given directly or mixed with food. The specific dosing, including the number of tablets and the frequency, depends on the pet's body weight and the type of parasite being treated, and it must be determined by a veterinarian. A typical dose for general deworming is often given as a single treatment.

Q: What are the possible side effects of Pratel?

A: When given at the recommended doses, Pratel is generally well-tolerated. The most common side effects reported are generally mild and temporary. These may include:

Digestive issues: Vomiting, diarrhea, or loss of appetite (anorexia).
Lethargy: Temporary tiredness or sluggishness.

If you notice persistent or severe side effects, you should contact your veterinarian.

Q: Can Pratel be used in pregnant or lactating animals?

A: The use of Pratel in pregnant or lactating (nursing) animals should be approached with caution and only on the direct advice and supervision of a veterinarian. Your vet will weigh the benefits of treating the infection against any potential risks to the mother and her offspring before recommending use.

Q: Does Pratel treat all types of worms?

A: No, Pratel is a broad-spectrum dewormer but it does not treat all types of parasitic worms. It is highly effective against:

Tapeworms
Roundworms
Hookworms

Pratel is not effective against heartworms or other parasites like coccidia or giardia. A different type of medication is required for those infections.

How should Pratel be stored and disposed of?

How to Store and Dispose of Pratel?

Pratel tablets must be stored under specific environmental constraints to maintain product stability and integrity, as defined by regulatory labeling.

Mandatory Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically between 15 C and 30 C (e.g., below 25 C or 30 C).
Protection	Keep protected from light and moisture.
Packaging	Store in the original, tightly closed container or outer carton.
Safety Isolation	Keep out of the sight and reach of children and animals; store separate from food and feed.

Halved tablets have a limited in-use stability of 1 month if stored correctly. Unused or expired Pratel, along with any waste materials, must be handled and disposed of in strict accordance with established local requirements and waste management protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Poland

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z